ReShape Lifesciences Inc. (RSLS) Announces 1:25 Reverse Share Split

ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, which will be effective for trading purposes upon the commencement of trading on May 9, 2025. At that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company’s outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole share. The number of authorized shares of common stock and preferred stock under the company’s certificate of incorporation will not be reduced in connection with the reverse stock split.

The reverse stock split was approved by ReShape Lifesciences’ stockholders at the company’s special meeting of stockholders held on April 1, 2025. ReShape Lifesciences stockholders will receive instructions from the company’s transfer agent, Equiniti Trust Company, LLC, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares. The new CUSIP number for the company’s common stock following the reverse stock split will be 76090R408.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Volitionrx Limited (VNRX) files for 10M share offering by selling stockholders
• BranchOut Food raises $2.5M in public stock offering